Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug Imatinib's Long-Term safety tracked in ongoing patients

NCT ID NCT01742299

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with no new treatment being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
imatinib (a targeted cancer drug taken as a daily pill)
What this could lead to
If successful, this study will confirm that long-term imatinib use is safe and continues to control GIST or CML, supporting its ongoing use.
What could go wrong
This is a roll-over safety study, not a test of new effectiveness. It only includes patients already benefiting, so results may not apply to all. Side effects remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive gastrointestinal stromal tumor Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIST AND CML

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210002, China

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Guangzhou, 510060, China

  • Novartis Investigative Site

    Shanghai, 200433, China

  • Novartis Investigative Site

    Helsinki, FIN-00029, Finland

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Pessac, 33604, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Hong Kong, 999077, Hong Kong

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, 400015, Romania

  • Novartis Investigative Site

    Bucharest, 022328, Romania

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Basel, 4031, Switzerland

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Novartis Investigative Site

    Manchester, M20 2BX, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • Sidney Kimmel CCC At JH

    Baltimore, Maryland, 21231, United States

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas, 77030, United States

  • University of California LA

    Los Angeles, California, 90095, United States

  • Weill Cornell Medical Center

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.